Raritan, NJ (December 4th, 2009) Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.
Findings from “CNS-Related Comorbidities in Individuals with Self-Reported Epilepsy – Data from the National Survey of Epilepsy, Comorbidities and Health Outcomes” will be detailed in a platform presentation on Dec. 7 at the 2009 American Epilepsy Society (AES) Annual Meeting in Boston. The analysis explores the importance of identifying these Central Nervous System (CNS)-related comorbid conditions, and their potential impact on the clinical management of epilepsy.
The survey results are one of eight presentations supported by Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) at the AES Meeting.
Saturday, Dec. 5: 1-8 p.m. (author presentations 2-3 p.m.)
Sunday, Dec. 6: 8 a.m. - 6 p.m. (author presentations 4-5 p.m.)
Monday, Dec. 7: Platform Presentations 4-6:15 p.m.
About Epilepsy
Epilepsy is one of the most common disorders of the nervous system, affecting more than 50 million people worldwide. As many as 200,000 Americans are diagnosed for the first time each year. Epilepsy produces seizures, which happen when a brief, strong surge of electrical activity affects part or all of the brain. The condition can develop at any time in life, but there is a particular susceptibility in young children and the elderly. Currently, there is no cure for epilepsy; however, medications help control seizure activity in the majority of people with this condition. It is important for people with epilepsy to be proactive in working with their healthcare professionals to determine the most effective treatment plan.
About Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a subsidiary of Johnson & Johnson, provides medicines for an array of health concerns, including central nervous system disorders, such as schizophrenia and epilepsy; metabolic diseases, such as diabetes; cardiovascular diseases; women's health; urology; gastrointestinal disorders; and infectious diseases. The company strives to provide innovative, high-quality, safe and effective treatments and continually seeks new opportunities to offer solutions for unmet health care needs. Ortho-McNeil-Janssen Pharmaceuticals, Inc. is headquartered in Raritan, N.J.
Contact:
Tricia Geoghegan
(Onsite at AES) (609) 462-8764
(609) 730-3746
tgeogheg@its.jnj.com
# # #
Raritan, NJ (December 4th, 2009) Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.
Findings from “CNS-Related Comorbidities in Individuals with Self-Reported Epilepsy – Data from the National Survey of Epilepsy, Comorbidities and Health Outcomes” will be detailed in a platform presentation on Dec. 7 at the 2009 American Epilepsy Society (AES) Annual Meeting in Boston. The analysis explores the importance of identifying these Central Nervous System (CNS)-related comorbid conditions, and their potential impact on the clinical management of epilepsy.
The survey results are one of eight presentations supported by Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) at the AES Meeting.
Saturday, Dec. 5: 1-8 p.m. (author presentations 2-3 p.m.)
Sunday, Dec. 6: 8 a.m. - 6 p.m. (author presentations 4-5 p.m.)
Monday, Dec. 7: Platform Presentations 4-6:15 p.m.
About Epilepsy
Epilepsy is one of the most common disorders of the nervous system, affecting more than 50 million people worldwide. As many as 200,000 Americans are diagnosed for the first time each year. Epilepsy produces seizures, which happen when a brief, strong surge of electrical activity affects part or all of the brain. The condition can develop at any time in life, but there is a particular susceptibility in young children and the elderly. Currently, there is no cure for epilepsy; however, medications help control seizure activity in the majority of people with this condition. It is important for people with epilepsy to be proactive in working with their healthcare professionals to determine the most effective treatment plan.
About Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a subsidiary of Johnson & Johnson, provides medicines for an array of health concerns, including central nervous system disorders, such as schizophrenia and epilepsy; metabolic diseases, such as diabetes; cardiovascular diseases; women's health; urology; gastrointestinal disorders; and infectious diseases. The company strives to provide innovative, high-quality, safe and effective treatments and continually seeks new opportunities to offer solutions for unmet health care needs. Ortho-McNeil-Janssen Pharmaceuticals, Inc. is headquartered in Raritan, N.J.
Contact:
Tricia Geoghegan
(Onsite at AES) (609) 462-8764
(609) 730-3746
tgeogheg@its.jnj.com
# # #